The most influential Megatrends set to shape the world through 2030, identified by Euromonitor International, help businesses better anticipate market developments and lead change for their industries.
Learn moreEuromonitor addresses your unique questions and challenges across all B2B and B2C industries and geographies through custom, tailor-made research projects, designed to your specific goals.
Learn moreJan 2018
US$1,325Added to Cart
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE!
Drug prices in developed markets will remain under pressure, in line with government-mandated initiatives, expected patent losses, and rising generic penetration. The key players are already losing their profits and thus ramp up advertising budgets and shift towards externalising R&D activities. However, in the longer run, companies can focus on caring for older consumers, and employing new technology either to reduce their manufacturing costs or to improve their products. .
Files are delivered directly into your account within a few minutes of purchase.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.
Pharmaceutical manufacturers will continue to face public sector regulatory pricing pressures, as governments aim to contain rising budget deficits. In addition, companies’ profit margins are expected to be negatively affected by expected patent losses. Finally, generic drug consumption and manufacturing is expected to intensify putting further pressure on drug prices.
As a direct consequence of intensifying pricing pressures, companies witnessed shrinking profit margins. As a result, pharmaceutical makers ramped up their advertising budgets to shield themselves from potential revenue losses. Some, however, maintained substantial investments in R&D hoping to develop the next blockbuster drug.
Although M&As somewhat slowed down in 2016, deal-making is expected to remain strong in the near future. This is partly due to the players’ strategic pursuit to externalise R&D. In addition, companies are increasingly willing to buy out innovation at an earlier stage of development.
Ageing populations in developed countries are expected to ensure continuous growth in demand for higher cost pharmaceuticals. As a result, biologics is set to be among the most lucrative drug sectors, with the greatest demand for oncology, diabetes, and rheumatoid arthritis treatments.
Pharmaceutical manufacturers can gain from Industry 4 solutions, as new technologies will provide significant production savings.
Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.